Volume 21 Issue 10
Oct.  2023
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2023  >  21(10): 1753-1756
LIU Yixian, CHEN Rong, CHENG Zhongping. Advances in immunotherapy in advanced or recurrent endometrial carcinoma[J]. Chinese Journal of General Practice, 2023, 21(10): 1753-1756. doi: 10.16766/j.cnki.issn.1674-4152.003217
Citation: LIU Yixian, CHEN Rong, CHENG Zhongping. Advances in immunotherapy in advanced or recurrent endometrial carcinoma[J]. Chinese Journal of General Practice, 2023, 21(10): 1753-1756. doi: 10.16766/j.cnki.issn.1674-4152.003217
shu

Advances in immunotherapy in advanced or recurrent endometrial carcinoma

doi: 10.16766/j.cnki.issn.1674-4152.003217

  • Department of Obstetrics and Gynecology, Shanghai Tenth People ' s Hospital, Shanghai 200072, China

Funds:

 2019SY053

  • Received Date: 2022-11-08
    Available Online: 2023-11-23
    Abstract
  • Endometrial cancer (EC) is one of the most common gynecological malignancies, and its incidence is increasing with the increase of obesity and aging population. Although the prognosis of early EC with surgical treatment is generally good, some patients still develop or develop metastatic or recurrent disease. In recent years, immunotherapy has made new progress and plays an important role in the treatment of advanced or recurrent EC. Immunotherapy mainly includes immune checkpoint inhibitors, such as programmed cell death 1/programmed cell death ligand-1 (PD-1/PD-L1) inhibitors, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors. Other immunotherapies include chimeric antigen receptor T cell (CAR-T) cell immunotherapy, tumor vaccine, etc. Combined with poly-ADP-ribose polymerase (PARP) inhibitors or targeted drugs is a hotspot, which can improve the objective response rate and produce additional effects or even synergistic effects. Immuno-checkpoint inhibitors are effective in the treatment of microsatellite unstable and mismatch repair defect endometrial carcinoma, but still need to be tested in other tumor types. The combination therapy of CTLA-4 and immunosuppressive checkpoint has its unique advantages, but its safety and efficacy need to be verified in a large number of trials. Combined with PARP inhibitors or targeted drugs, drug types and dosages need to be explored in order to achieve optimal efficacy with minimal side effects. As for cancer vaccine, studies have confirmed that the vaccine can prevent EC recurrence, but its safety and effectiveness still need to be verified. In the future, the study of immune-related biomarkers will also help to predict the prognosis of EC treatment, which is of great significance for the study of immunotherapy.

     

    • FullText(HTML)
  • loading
    • References(32)
  • [1]
    SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics, 2019[J]. CA Cancer J Clin, 2019, 69(1): 7-34. doi: 10.3322/caac.21551
    [2]
    ZHAO D L, ZHANG Z, WANG Z H, et al. Diagnosis and prediction of endometrial carcinoma using machine learning and artificial neural networks based on public databases[J]. Genes (Basel), 2022, 13(6): 935. doi: 10.3390/genes13060935
    [3]
    DE BOER S M, POWELL M E, MILESHKIN L, et al. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial[J]. Lancet Oncol, 2019, 20(9): 1273-1285. doi: 10.1016/S1470-2045(19)30395-X
    [4]
    MUTLU L, HAROLD J, TYMON-ROSARIO J, et al. Immune checkpoint inhibitors for recurrent endometrial cancer[J]. Expert Rev Anticancer Ther, 2022, 22(3): 249-258. doi: 10.1080/14737140.2022.2044311
    [5]
    GOLDBERG K B, BLUMENTHAL G M, MCKEE A E, et al. The FDA Oncology Center of Excellence and precision medicine[J]. Exp Biol Med (Maywood), 2018, 243(3): 308-312. doi: 10.1177/1535370217740861
    [6]
    DE FELICE F, MARCHETTI C, PALAIA I, et al. Immune check-point in cervical cancer[J]. Crit Rev Oncol Hematol, 2018, 129: 40-43. doi: 10.1016/j.critrevonc.2018.06.006
    [7]
    GREEN A K, FEINBERG J, MAKKER V. A review of immune checkpoint blockade therapy in endometrial cancer[J]. Am Soc Clin Oncol Educ Book, 2020, 40: 1-7.
    [8]
    BARBER E L, CHEN S Q, PINEDA M J, et al. Clinical and biological activity of chemoimmunotherapy in advanced endometrial adenocarcinoma: a phase ii trial of the big ten cancer research consortium[J]. Cancer Res Commun, 2022, 2(10): 1293-1303. doi: 10.1158/2767-9764.CRC-22-0147
    [9]
    KUMAR S, GHOSH S, SHARMA G, et al. Preclinical characterization of dostarlimab, a therapeutic anti-PD-1 antibody with potent activity to enhance immune function in in vitro cellular assays and in vivo animal models[J]. MAbs, 2021, 13(1): 1954136. DOI: 10.1080/19420862.2021.1954136.
    [10]
    OAKNIN A, TINKER A V, GILBERT L, et al. Clinical activity and safety of the anti-programmed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair-deficient endometrial cancer: a nonrandomized phase 1 clinical trial[J]. JAMA Oncol, 2020, 6(11): 1766-1772. doi: 10.1001/jamaoncol.2020.4515
    [11]
    MATHEWS C, LORUSSO D, COLEMAN R L, et al. An indirect comparison of the efficacy and safety of dostarlimab and doxorubicin for the treatment of advanced and recurrent endometrial cancer[J]. Oncologist, 2022, 27(12): 1058-1066. doi: 10.1093/oncolo/oyac188
    [12]
    KONSTANTINOPOULOS P A, LUO W X, LIU J F, et al. Phase Ⅱ study of avelumab in patients with mismatch repair deficient and mismatch repair proficient recurrent/persistent endometrial cancer[J]. J Clin Oncol, 2019, 37(30): 2786-2794. doi: 10.1200/JCO.19.01021
    [13]
    ANTILL Y, KOK P S, ROBLEDO K, et al. Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial[J]. J Immunother Cancer, 2021, 9(6): e002255. DOI: 10.1136/jitc-2020-002255.
    [14]
    FLEMING G, EMENS L, EDER J, et al. Clinical activity, safety and biomarker results from a phase Ia study of atezolizumab(atezo) in advanced/recurrent endometrial cancer(rEC)[J]. J Clin Oncol, 2017, 35(15_suppl): 5585. doi: 10.1200/JCO.2017.35.15_suppl.5585
    [15]
    HOSSEINI A, GHARIBI T, MAROFI F, et al. CTLA-4: from mechanism to autoimmune therapy[J]. Int Immunopharmacol, 2020, 80: 106221. DOI: 10.1016/j.intimp.2020.106221.
    [16]
    OH M S, CHEN Y K. Deep and durable response with combination CTLA-4 and PD-1 blockade in Mismatch Repair (MMR)-proficient endometrial cancer[J]. J Immunother, 2019, 42(2): 51-54. doi: 10.1097/CJI.0000000000000244
    [17]
    RUBINSTEIN M M, CAIRD I, ZHOU Q, et al. A phase Ⅱ trial of durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial carcinoma and endometrial carcinosarcoma[J]. J Clin Oncol, 2019, 37: 5582. doi: 10.1200/JCO.2019.37.15_suppl.5582
    [18]
    MAHMOOD S S, CHEN C L, SHAPNIK N, et al. Myocarditis with tremelimumab plus durvalumab combination therapy for endometrial cancer: a case report[J]. Gynecol Oncol Rep, 2018, 25: 74-77. doi: 10.1016/j.gore.2018.05.014
    [19]
    MILIOTOU A N, PAPADOPOULOU L C. CAR T-cell therapy: a new era in cancer immunotherapy[J]. Curr Pharm Biotechnol, 2018, 19(1): 5-18. doi: 10.2174/1389201019666180418095526
    [20]
    SCHEPISI G, CASADEI C, TOMA I, et al. Immunotherapy and its development for gynecological (ovarian, endometrial and cervical) tumors: from immune checkpoint inhibitors to Chimeric Antigen Receptor (CAR)-T cell therapy[J]. Cancers (Basel), 2021, 13(4): 804. doi: 10.3390/cancers13040804
    [21]
    CÉSAIRE M, THARIAT J, CANDÉIAS S M, et al. Combining PARP inhibition, radiation, and immunotherapy: a possible strategy to improve the treatment of cancer?[J]. Int J Mol Sci, 2018, 19(12): 3793. doi: 10.3390/ijms19123793
    [22]
    DING L Y, KIM H J, WANG Q W, et al. PARP inhibition elicits STING-dependent antitumor immunity in brca1-deficient ovarian cancer[J]. Cell Rep, 2018, 25(11): 2972-2980. doi: 10.1016/j.celrep.2018.11.054
    [23]
    NATARAJAN U, VENKATESAN T, DHANDAYUTHAPANI S, et al. Differential mechanisms involved in RG-7388 and Nutlin-3 induced cell death in SJSA-1 osteosarcoma cells[J]. Cell Signal, 2020, 11(75): 109742. DOI: 10.1016/j.cellsig.2020.109742.
    [24]
    SHEN K, YANG L, LI F Y, et al. Research progress of PARP inhibitor monotherapy and combination therapy for endometrial cancer[J]. Curr Drug Targets, 2022, 23(2): 145-155. doi: 10.2174/1389450122666210617111304
    [25]
    POST C C B, WESTERMANN A M, BOERE I A, et al. Efficacy and safety of durvalumab with olaparib in metastatic or recurrent endometrial cancer (phase Ⅱ DOMEC trial)[J]. Gynecol Oncol, 2022, 165(2): 223-229. doi: 10.1016/j.ygyno.2022.02.025
    [26]
    KONSTANTINOPOULOS P A, GOCKLEY A A, XIONG N, et al. Evaluation of treatment with talazoparib and avelumab in patients with recurrent mismatch repair proficient endometrial cancer[J]. JAMA Oncol, 2022, 8(9): 1317-1322. doi: 10.1001/jamaoncol.2022.2181
    [27]
    MIMCHELL T C, HAMID O, SMITH D C, et al. Epacadostat plus pembrolizumab in patients with advanced solid tumors: phase Ⅰ results from a multicenter, open-label phase Ⅰ/Ⅱ trial (ECHO-202/KEYNOTE-037)[J]. J Clin Oncol, 2018, 36(32): 3223-3230. doi: 10.1200/JCO.2018.78.9602
    [28]
    MAKKER V, RASCO D, VOGELZANG N J, et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial[J]. Lancet Oncol, 2019, 20(5): 711-718. doi: 10.1016/S1470-2045(19)30020-8
    [29]
    ZIMMER A S, NICHOLS E, CIMINO-MATHEWS A, et al. A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women ' s cancers with biomarker analyses[J]. J Immunother Cancer, 2019, 7(1): 197. doi: 10.1186/s40425-019-0680-3
    [30]
    KOOSHKAKI O, DERAKHSHANI A, SAFARPOUR H, et al. The latest findings of PD-1/PD-L1 inhibitor application in gynecologic cancers[J]. Int J Mol Sci, 2020, 21(14): 5034. doi: 10.3390/ijms21145034
    [31]
    徐力, 聂柳燕, 汪胡燕, 等. 自身免疫性疾病中程序性细胞死亡因子1及其配体的研究进展[J]. 中华全科医学, 2022, 20(5): 832-835, 843. doi: 10.16766/j.cnki.issn.1674-4152.002466

    XU L, NIE L Y, WANG H Y, et al. Research progress of programmed cell death-1 and its ligand in autoimmune diseases[J]. Chinese Journal of General Practice, 2022, 20(5): 832-835, 843. doi: 10.16766/j.cnki.issn.1674-4152.002466
    [32]
    高五岳, 郭园园, 刘贝贝, 等. 不同距离癌旁组织PD-1和PD-L1表达对肾部分切除术边距选择的临床意义[J]. 中华全科医学, 2019, 17(12): 2004-2007, 2034. doi: 10.16766/j.cnki.issn.1674-4152.001113

    GAO W Y, GUO Y Y, LIU B B, et al. The clinical significances of PD-1 and PD-L1 expressions in different distant tumor adjacent tissues for selecting safe surgical margins in partial nephrectomy[J]. Chinese Journal of General Practice, 2019, 17(12): 2004-2007, 2034. doi: 10.16766/j.cnki.issn.1674-4152.001113
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (181) PDF downloads(24) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return